HC Wainwright Analysts Increase Earnings Estimates for GALT

Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) – Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Galectin Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($0.26) per share for the year, up from their prior estimate of ($0.30). The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q4 2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.16) EPS.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01.

A number of other equities analysts have also issued reports on GALT. Zacks Research upgraded shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Monday, September 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $11.00.

View Our Latest Stock Report on Galectin Therapeutics

Galectin Therapeutics Stock Down 3.6%

Shares of NASDAQ GALT opened at $2.91 on Wednesday. Galectin Therapeutics has a fifty-two week low of $2.03 and a fifty-two week high of $7.13. The firm’s 50-day simple moving average is $3.59 and its 200 day simple moving average is $3.22. The stock has a market cap of $191.65 million, a P/E ratio of -8.56 and a beta of 0.53.

Hedge Funds Weigh In On Galectin Therapeutics

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Galectin Therapeutics by 101.3% in the third quarter. Russell Investments Group Ltd. now owns 8,001 shares of the company’s stock valued at $31,000 after buying an additional 4,027 shares during the period. Argyle Capital Partners LLC acquired a new position in Galectin Therapeutics during the second quarter worth about $62,000. Archer Investment Corp acquired a new position in Galectin Therapeutics during the second quarter worth about $81,000. Bank of America Corp DE grew its holdings in Galectin Therapeutics by 114.9% during the first quarter. Bank of America Corp DE now owns 53,862 shares of the company’s stock worth $150,000 after acquiring an additional 28,799 shares during the period. Finally, Hopwood Nicholas Hunter bought a new stake in Galectin Therapeutics in the second quarter worth about $322,000. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

Read More

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.